Antibodies as Drugs: Innovative Formats, Design and Engineering (Q3)
February 17-20, 2025
| Keystone Resort, Keystone, CO, United States
Jean-Philippe Julien and Katherine Harris
Scholarship Deadline: Nov. 27, 2024 | Abstract Deadline: Jan. 28, 2025 | Early Registration Deadline: Dec. 24, 2024
Monday, February 17, 2025
| 4:00–8:00 PM |
Registration |
Longs Peak Foyer |
| 6:00–8:00 PM |
Welcome Mixer |
Longs Peak Foyer |
Tuesday, February 18, 2025
| 7:00–8:00 AM |
Breakfast |
Shavano/Torreys/Red Cloud |
| 8:00–9:00 AM |
Welcome and Keynote Address |
Grays Peak |
| |
* Katherine Harris, Rondo Therapeutics
Session Chair |
|
| |
* Jean-Philippe Julien, Hospital for Sick Children Research Institute
Session Chair |
|
| |
Koustubh Ranade, Immunocore
Monoclonal Antibodies & TCRs: Shaping the Future of Therapeutic Design |
|
| 9:00–11:00 AM |
Antibody-Based Protein Degraders for Therapeutics Development |
Grays Peak |
| |
Leo James, MRC Laboratory of Molecular Biology
Remote Presentation: Trim-Away: TRIM21-based Modalities for Intracellular Targeted Protein Degradation |
|
| |
Jithu Krishna, University of Massachusetts, Amherst
Short Talk: Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors |
|
| |
* James A Wells, University of California, San Francisco
Novel Approaches for Extracellular Targeted Protein Degradation (eTPD) |
|
| 9:30–9:50 AM |
Coffee Break |
Longs Peak Foyer |
| 11:15–1:00 PM |
Poster Setup |
Shavano/Torreys/Red Cloud |
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Shavano/Torreys/Red Cloud |
| 1:30–3:30 PM |
Symposia Spotlight 1: Preclinical Development of Antibody Therapeutics: From Discovery to IND |
Grays Peak |
| |
* Kirstin A Zettlitz, Beckman Research Institute of the City of Hope
Fc-engineering to Increase the Therapeutic Index for Antibody Fragment-based Radioimmunotherapy |
|
| |
Daniela Cipolletta, Seismic Therapeutic
S-4321, A Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease |
|
| |
Cory Brooks, California State University, Fresno
Targeting MUC16 in Pancreatic Cancer: Structural and Functional Analysis of the Humanized AR9.6 Antibody |
|
| |
Gualberto G. Gonzalez-Sapienza, Facultad de Quimica, UdelaR
Targeting PD-L1 Blockade to Dendritic Cells through Simultaneous Binding to CD11c Enhances Antitumor Efficacy |
|
| |
Melanie Walker, RenBio
Development of an Influenza Neutralizing Antibody Cocktail using DNA-based Delivery |
|
| |
Stefan Schmidt, Evitira AG
Trans-splicing Mediated Recombination to Generate Multi-specific Antibodies |
|
| |
Isabel Grace Elliott, University of Southampton
Structure-guided Disulfide Engineering Restricts Antibody Conformation to Elicit TNFR Agonism in Anti-cancer Therapeutics |
|
| 3:30–4:30 PM |
Career Roundtable (Joint) |
Grays Peak |
| |
Luka Kulic, F. Hoffmann-La Roche Ltd.
Therapeutic Area Leader Dementias, Expert Scientist and Medical Director |
|
| |
Kylie Chew, Denali Therapeutics
Principal Scientist |
|
| |
Russell K Pachynski, Washington University in St. Louis
Associate Professor |
|
| |
Roosmarijn E Vandenbroucke, VIB and Ghent University
Group Leader & Professor |
|
| 4:30–5:00 PM |
Coffee Available |
Longs Peak Foyer |
| 5:00–6:45 PM |
New Developments in Antibody Drug Conjugate Technology |
Grays Peak |
| |
Seema Kantak, Exelixis
Discovery of XB010, a Next Generation 5T4-targeting ADC |
|
| |
Scott Lesley, InduPro
Proximity-based Bispecific Antibody Strategies to Address Disease |
|
| 7:00–8:00 PM |
Cocktail Hour Sponsored by Nicoya |
Shavano/Torreys/Red Cloud |
| 7:05–8:05 PM |
Dinner |
Shavano/Torreys/Red Cloud |
| 7:30–10:00 PM |
Poster Session 1 |
Shavano/Torreys/Red Cloud |
Wednesday, February 19, 2025
| 7:00–8:00 AM |
Breakfast |
Shavano/Torreys/Red Cloud |
| 8:00–11:00 AM |
Pushing the Boundaries of Biologics Towards Precision |
Grays Peak |
| |
Benjamí Oller-Salvia, Ramon Llull University
Novel Approaches for Conditionally-Active and Brain-Permeable Antibodies |
|
| |
* Mark S Cragg, University of Southampton
Developing Immunostimulating Antibodies to Deliver Agonism Without Toxicity |
|
| |
Marvin Gee, 3T Biosciences
TCR Biologics |
|
| |
David G Kugler, Cartography Biosciences
Identifying & Building Around Optimal Targets for Oncology Therapies |
|
| |
Vanessa Laversenne, Broad Institute of Harvard and MIT
Short Talk: Evaluating Peripheral Delivery of Anti-PrP Antibody AZ59 for Brain PrP Targeting and Therapeutic Potential in Prion Disease |
|
| |
Constantinos_Kurt Wibmer, Wits Health Consortium
Short Talk: A Monoclonal Antibody that Neutralizes both Long- and Short-chain Three Finger Snake Venom Neurotoxins |
|
| 9:00–9:20 AM |
Coffee Break |
Longs Peak Foyer |
| 9:20–9:25 AM |
Award Recipient Acknowledgement |
Grays Peak |
| 11:00–5:00 PM |
On Own for Lunch |
|
| 4:30–5:00 PM |
Coffee Available |
Longs Peak Foyer |
| 5:00–7:00 PM |
Technologies to Increase Drug Accessibility against Infectious Diseases on a Global Scale |
Grays Peak |
| |
Semiramis Yilmaz, VIB-UGent Center for Medical Biotechnology
A Yeast Manufacturing Platform for VHH-Fc Type Molecules |
|
| |
Anja F Hohmann, Be Biopharma
Genetically Engineered B Cell Medicines for Sustained in Vivo Delivery of Therapeutic Biologics |
|
| |
* Christopher O Barnes, Stanford University
Antibody Therapeutics Against Respiratory RNA Viruses |
|
| |
Jean-Philippe Julien, Hospital for Sick Children Research Institute
Antibody-based Strategies to Block the Transmission of Malaria |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
Shavano/Torreys/Red Cloud |
| 7:30–10:00 PM |
Poster Session 2 |
Shavano/Torreys/Red Cloud |
Thursday, February 20, 2025
| 7:00–8:00 AM |
Breakfast |
Shavano/Torreys/Red Cloud |
| 8:00–10:30 AM |
Therapeutic Applications of Fc Domain Engineering |
Grays Peak |
| |
* E. Sally Ward, University of Southampton
Targeting FcRn for the Generation of Therapeutics for Antibody-Mediated Disease |
|
| |
John R. Desjarlais, Xencor, Inc.
Optimization and Application of Fc-Containing Bispecific Antibodies |
|
| |
Karen Silence, arGEN-X BVBA
Engineering of Antibodies for Optimal FcRn Engagement |
|
| |
Ibo Janssens, Argenx
Short Talk: How Format Impacts Activity: Structure-activity Relationship for Optimal FcRn Engagement of Fc-based Therapeutics |
|
| |
Stefan Weise, Roche Diagnostics GmbH
Short Talk: Structure-PK Relationship: Complex Antibody Format Affects Pharmacokinetic Properties via FcRn Recycling |
|
| 9:00–9:20 AM |
Coffee Break |
Longs Peak Foyer |
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Leveraging AI and ML in Antibody Discovery, Engineering and Beyond |
Grays Peak |
| |
Joel Bard, Pfizer
Biocheminformatics – Enabling Data Science for Macromolecular Drug Discovery |
|
| |
* Karen Duffy, Manifold Bio
Integrating High-throughput in vivo Screening with AI-guided Protein Design to Select Brain Shuttles with Optimal Pharmacokinetics, Biodistribution, and Other Drug-like Properties |
|
| |
Nitesh Mishra, The Scripps Research Institute
Rapid AI-Driven Design of Broadly Neutralizing Antibodies Targeting the HIV-1 Envelope Glycoprotein |
|
| |
Sameer Soi, Abalone Bio
Harnessing Protein Language Models and Large-Scale Functional Data to Generate Novel, Functionally Active Antibody Therapeutics |
|
| |
Ariel Tennenhouse, Weizmann Institute of Science
One-shot Optimization of Antibody Developability and Affinity by Computational Design |
|
| |
* Peter Tessier, University of Michigan
Optimization of Mono- and Multi-Specific Antibodies Using Machine Learning and Atomistic Design |
|
| |
Greg Mirando, Precision BioTools
Targeting KRAS Mutation Diversity with Epivolve®: A Novel Approach for Precision Cancer Therapeutics and Diagnostics |
|
| |
Deborah Flusberg, Certara
Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window |
|
| 4:30–5:00 PM |
Coffee Available |
Longs Peak Foyer |
| 5:00–6:45 PM |
Novel Antibody Therapies and Combinations |
Grays Peak |
| |
Rony Dahan, Weizmann Institute of Science
Bispecific Immune Synapse Engagers for Cancer Immunotherapy |
|
| |
Katherine Harris, Rondo Therapeutics
Bispecific Antibody Combination Strategies for Treating Solid Tumors |
|
| |
* Katherine Cygnar, Regeneron Pharmaceuticals
Optimizing BBB-Crossing Antibodies and Antibody-Targeted Cargo |
|
| |
Mike Wan, Gilead Science
Short Talk: Utilizing Cis-binding in T Cell Engagers: Theoretical Modeling to Guide 2+1 and Multi-specific TCE Design |
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
Grays Peak |
| 7:00–8:00 PM |
Social Hour with Lite Bites |
Shavano/Torreys/Red Cloud |
| 8:00–9:00 PM |
Entertainment |
Longs Peak |
| 8:00–9:00 PM |
Cash Bar |
Shavano/Torreys/Red Cloud |
Friday, February 21, 2025
